• Ocumension Therapeutics received NMPA CDE acceptance for a domestic registration filing for dexamethasone intraocular suspension injection OT-502 (DEXYCU).
• The filing was accepted as a chemical drug Class 4 application.
• The product was submitted for China’s priority review list, completing the public notice process.
• Domestic manufacturing would replace imported supply for China, supporting supply stability and lowering production and logistics costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumension Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260901-12314182), on September 01, 2026, and is solely responsible for the information contained therein.